Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
The weight-loss-drug manufacturer failed to excite investors hoping for a turnaround.
Finance & markets
Monday, 21 September 2026
Independent coverage of global markets, trade and finance
Finance & markets
Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
The weight-loss-drug manufacturer failed to excite investors hoping for a turnaround.